Startup financing continues to support rare disease targets. OMass secured $310M to advance a therapy for a rare endocrine disorder, aiming to become an alternative to Neurocrine Biosciences’ only FDA-approved congenital adrenal hyperplasia therapy. The funding also signals competitive pressure on pipeline incumbents: the report notes Vertex Pharmaceuticals could potentially contest the space with a candidate stemming from a recent acquisition. For investors and peers, the critical point is how large late-stage funding is being deployed to accelerate development in endocrine rare diseases with clear regulatory precedents. With $310M backing, the next milestones for the program will likely be development of clinical evidence packages that demonstrate differentiation in efficacy, tolerability, or dosing convenience relative to current standards of care. Overall, the deal emphasizes that rare endocrine markets remain attractive for platform-like differentiation and that capital intensity is increasing for first-to-market or replacement strategies.